GlassScriptPhysician profile
William H Fredriksson
NPI 1841280872
$1,874.96
in general payments reported to CMS, 2019-2025
24 companies · $604 in 2025
The $604 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $3.82 · 2021: $19.49 · 2022: $351 · 2023: $299 · 2024: $471 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.86 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $402.08 | 2019-2025 | |
| Dornier Medtech America, INC | $238.35 | 2025 | Dornier Medtech |
| Janssen Biotech, INC. | $153.38 | 2019-2025 | Erleada |
| Coloplast Corp | $145.95 | 2022-2025 | Titan, Speedicath |
| Medtronic, INC. | $137.04 | 2021-2022 | |
| Procept Biorobotics Corporation | $116.98 | 2024 | Aquabeam System |
| Teleflex LLC | $107.82 | 2022-2025 | Urolift, Barrigel |
| Novartis Pharmaceuticals Corporation | $86.86 | 2022-2025 | |
| Boston Scientific Corporation | $70.35 | 2024-2025 | Ams 700 |
| Pfizer INC. | $69.83 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $62.12 | 2023-2025 | Orgovyx |
| Axonics, INC. | $53.70 | 2022-2024 | Axonics, Bulkamid |
| Laborie Medical Technologies Corp. | $45.73 | 2023-2025 | |
| Astellas Pharma US INC | $44.26 | 2022-2025 | Xtandi, Myrbetriq |
| Antares Pharma, INC. | $31.66 | 2022-2023 | Nocdurna, Tlando, Xyosted |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $23.53 | 2024 | |
| Urovant Sciences INC | $23.15 | 2022 | |
| Allergan, INC. | $16.69 | 2019 | |
| Myovant Sciences INC. | $15.90 | 2022 | |
| Medtronic USA, INC. | $14.02 | 2019 | |
| Merck Sharp & Dohme LLC | $11.74 | 2022 | |
| Travere Therapeutics, INC. | $3.82 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$203,770.64 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Fredriksson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.